Abstract
We read with interest the article by Bloom et al reporting liver biochemistry–associated trends, etiologies, and outcomes in 60 patients with coronavirus disease 2019 (COVID‐19). The authors reported that 69% of the patients had abnormal liver function tests (LFTs) on admission and 93% during their hospital stay, with an aspartate aminotransferase (AST) predominance. These results are similar to our own experience of 234 patients admitted with COVID‐19 according to World Health Organization (WHO) diagnostic guidelines.